|
|
|
Licensing & Acquisition
Trinity provides meticulous and objective assessments of US and global licensing and acquisition (L&A) opportunities. We pride ourselves on a rapid response to client needs and on our experience in delivering top quality work in high-pressure situations for difficult projects. Trinity has completed over 100 assessments in a vast array of therapeutic areas and technology platforms. Major areas of focus include oncology, autoimmune (neurology, rheumatology, gastroenterology, and dermatology), CNS, cardiovascular, metabolic, anti-infective, pain and analgesia, pulmonary, and men's and women's health. The breadth of our expertise makes us an immediate contributor with minimal lag time.
At Trinity, we combine proficiency in science and business strategy, resulting in recommendations that are balanced and comprehensive in technical and commercial attributes. Trinity works on short- (filed/launched), mid- (Phase IIb III), and long-term (preclinical Phase IIa) opportunities, and will provide strategic recommendations from opportunity identification through deal negotiation. Because of the increasing competitiveness of L&A in the pharmaceutical industry, independent third-party evaluation is essential for most, if not all, opportunities.
CASE EXAMPLE
Situation
An industry merger necessitated the termination of an out-licensing agreement for a currently marketed product. In addition to multiple companies competing for the U.S. license, the product performance to date had been sub-optimal. Offers needed to be received immediately to avoid disruption of the selling effort following the termination of the agreement. Our client was a strong strategic fit as a U.S. partner.
Approach
Trinity was responsible for due diligence surrounding market outlook and rationale for poor performance. Through a compilation of primary and secondary data and team input, we completed a risk analysis and financial valuation for the product.
Result
We concluded that the product suffered from a lack of voice in the physician community and proper selling focus would improve the situation. At launch, pricing and strategic customer tactics were ineffective. Our client successfully won the U.S. rights to the target product and has seamlessly integrated it into their sales force.
|
|
